Clinical Trial Search

Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: Complete Response Rate — 83 percentage of participants

Primary: Complete Remission Rate: Percentage of Participants With Complete Remission (CR) — 85 percentage of participants

Primary: Overall Response Rate — 11; 2 Participants

Primary: Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen — 100; 100; 100; 100 percentage of patients

Primary: Participants With a Response — 9 Participants

Primary: Complete Remission — 10 participants

Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants

Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants

Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Progression-free Survival — 89 percentage of participants

Primary: Progression-free Survival at 2 Years — 76; 80 percentage of participants — p=0.11

Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Median Progression Free Survival (PFS) — 13.8 years

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Overall Response Rate (ORR) — 0.05 Proportion of participants

Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants

Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects